8-K 1 ea152579-8k_ahrenacq.htm CURRENT REPORT

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): December 17, 2021 (December 14, 2021)

 

 

 

AHREN ACQUISITION CORP.

(Exact name of registrant as specified in its charter)

 

 

 

Cayman Islands   001-41162   98-1594455
(State or other jurisdiction
of incorporation)
  (Commission
File Number)
  (IRS Employer
Identification No.)

 

Boundary Hall, Cricket Square
Grand Cayman, KY1-1102

(Address of principal executive offices, including zip code)

 

Registrant’s telephone number, including area code: (646) 480-0033

 

Not Applicable
(Former name or former address, if changed since last report)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Units, each consisting of one Class A ordinary share, $0.0001 par value, and one-half of one redeemable warrant   AHRNU   The Nasdaq Stock Market LLC
Class A ordinary shares, par value $0.0001 par value   AHRN   The Nasdaq Stock Market LLC
Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share   AHRNW   The Nasdaq Stock Market LLC

  

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company þ

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

  

 

 

Item 1.01. Entry into a Material Definitive Agreement.

 

On December 17, 2021, Ahren Acquisition Corp. (the “Company”) consummated its initial public offering (“IPO”) of 29,999,800 units (the “Units”), including the issuance of 2,499,800 Units as a result of the underwriters’ exercise in part of their option to purchase additional Units. Each Unit consists of one Class A ordinary share of the Company, par value $0.0001 per share (the “Class A Ordinary Shares”), and one-half of one redeemable warrant of the Company (each whole warrant, a “Warrant”), with each Warrant entitling the holder thereof to purchase one Class A Ordinary Share for $11.50 per share, subject to adjustment. The Units were sold at a price of $10.00 per Unit, generating gross proceeds to the Company of $299,998,000.

 

In connection with the IPO, the Company entered into the following agreements, forms of which were previously filed as exhibits to the Company’s Registration Statement on Form S-1 (File No. 333-261334) for the IPO, initially filed with the U.S. Securities and Exchange Commission (the “Commission”) on November 24, 2021, as amended (the “Registration Statement”):

 

  An Underwriting Agreement, dated December 14, 2021, by and between the Company and Citigroup Global Markets Inc., as representative of the underwriters, a copy of which is attached as Exhibit 1.1 hereto and incorporated herein by reference.

 

  A Warrant Agreement, dated December 14, 2021, by and between the Company and Continental Stock Transfer & Trust Company, as warrant agent, a copy of which is attached as Exhibit 4.1 hereto and incorporated herein by reference.

 

  A Letter Agreement, dated December 14, 2021 (the “Letter Agreement”), by and among the Company, its executive officers, its directors, the Company’s sponsor, AACS LP (the “Sponsor”) and BDTCP Investments 2018, LLC, a copy of which is attached as Exhibit 10.1 hereto and incorporated herein by reference.

 

  An Investment Management Trust Agreement, dated December 14, 2021, by and between the Company and Continental Stock Transfer & Trust Company, as trustee, a copy of which is attached as Exhibit 10.2 hereto and incorporated herein by reference.

 

  A Registration Rights Agreement, dated December 14, 2021, by and among the Company, the Sponsor and the Holders signatory thereto, a copy of which is attached as Exhibit 10.3 hereto and incorporated herein by reference.

 

  A Private Placement Warrants Purchase Agreement, dated December 14, 2021, by and between the Company and the Sponsor (the “Private Placement Warrants Purchase Agreement”), a copy of which is attached as Exhibit 10.4 hereto and incorporated herein by reference.

 

  An Administrative Services Agreement, dated December 14, 2021, by and between the Company and the Sponsor, a copy of which is attached as Exhibit 10.5 hereto and incorporated herein by reference.

 

1

 

Item 3.02. Unregistered Sales of Equity Securities.

 

Simultaneously with the closing of the IPO, pursuant to the Private Placement Warrants Purchase Agreement, the Company completed the private sale of 15,249,920 warrants (the “Private Placement Warrants”) to the Sponsor at a purchase price of $1.00 per Private Placement Warrant, generating gross proceeds to the Company of $15,249,920. The Private Placement Warrants are identical to the Warrants included as part of the Units sold in the IPO, except that the Private Placement Warrants, so long as they are held by the Sponsor or its permitted transferees, (i) are not redeemable by the Company, (ii) may not (including the Class A Ordinary Shares issuable upon exercise of the warrants), subject to certain limited exceptions, be transferred, assigned or sold until 30 days after the completion of the Company’s initial business combination, (iii) may be exercised on a cashless basis and (iv) are entitled to registration rights. No underwriting discounts or commissions were paid with respect to such sale. The issuance of the Private Placement Warrants was made pursuant to the exemption from registration contained in Section 4(a)(2) of the Securities Act of 1933, as amended.

 

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On December 14, 2021, in connection with the IPO, Jeremy Darroch, Kathleen Hughes, Uwe Krüger and Donald McLellan were appointed to the board of directors of the Company (the “Board”) and Sir Shankar Balasubramanian was appointed to the office of Science Partner. Mr. Darroch, Ms. Hughes, Mr. Krüger and Mr. McLellan are independent directors. Effective December 14, 2021, Jeremy Darroch, Kathleen Hughes and Uwe Krüger were appointed to the Board’s Audit Committee and Jeremy Darroch, Kathleen Hughes, Uwe Krüger and Donald McLellan were appointed to the Board’s Compensation Committee, with Jeremy Darroch serving as chair of the Audit Committee and Donald McLellan serving as chair of the Compensation Committee.

 

Following the appointment of Jeremy Darroch, Kathleen Hughes, Uwe Krüger and Donald McLellan, the Board is comprised of the following three classes: the term of office of the first class of directors, Class I, consists of Jeremy Darroch and Kathleen Hughes and will expire at the Company’s first annual meeting of shareholders; the term of office of the second class of directors, Class II, consists of Uwe Krüger and Donald McLellan and will expire at the Company’s second annual meeting of shareholders; and the term of office of the third class of directors, Class III, consists of Alice Newcombe-Ellis and Elliot Richmond and will expire at the Company’s third annual meeting of shareholders.

  

On December 14, 2021, in connection with their appointments, each of the members of the Board and each officer of the Company entered into the Letter Agreement as well as an indemnity agreement with the Company in the form previously filed as Exhibit 10.5 to the Registration Statement.

 

Other than the foregoing, none of the directors or officers are party to any arrangement or understanding with any person pursuant to which they were appointed as directors or officers, nor are they party to any transactions required to be disclosed under Item 404(a) of Regulation S-K involving the Company.

 

The foregoing descriptions of the Letter Agreement and the form of indemnity agreement do not purport to be complete and are qualified in their entireties by reference to the Letter Agreement and form of indemnity agreement, copies of which are attached as Exhibit 10.1 hereto and Exhibit 10.5 to the Registration Statement, respectively, and are incorporated herein by reference.

 

2

 

Item 5.03. Amendments to Certificate of Incorporation or Bylaws; Change in Fiscal Year.

 

On December 14, 2021, in connection with the IPO, the Company adopted its Amended and Restated Memorandum and Articles of Association (the “Amended Charter”), effective the same day. The terms of the Amended Charter are set forth in the Registration Statement and are incorporated herein by reference. A copy of the Amended Charter is attached as Exhibit 3.1 hereto and incorporated herein by reference.

 

Item 8.01. Other Events.

 

A total of $305,997,960, comprised of $293,998,040 of the proceeds from the IPO (which amount includes $10,499,930 of the underwriters’ deferred discount) and $11,999,920 of the proceeds of the sale of the Private Placement Warrants, was placed in a U.S.-based trust account at J.P. Morgan Chase Bank, N.A. maintained by Continental Stock Transfer & Trust Company, acting as trustee. Except with respect to interest earned on the funds held in the trust account that may be released to the Company to pay its taxes and up to $100,000 of interest to pay dissolution expenses, the funds held in the trust account will not be released from the trust account until the earliest of (i) the completion of the Company’s initial business combination, (ii) the redemption of any of the Class A Ordinary Shares included in the Units sold in the IPO (the “public shares”) properly submitted in connection with a shareholder vote to amend the Company’s Amended Charter (A) to modify the substance or timing of the Company’s obligation to redeem 100% of the public shares if it does not complete its initial business combination within 18 months from the closing of the IPO or (B) with respect to any other material provisions relating to shareholders’ rights or pre-initial business combination activity or (iii) the redemption of the Company’s public shares if it is unable to complete its initial business combination within 18 months from the closing of the IPO, subject to applicable law.

 

On December 14, 2021, the Company issued a press release announcing the pricing of the IPO, a copy of which is attached as Exhibit 99.1 to this Current Report on Form 8-K.

 

On December 17, 2021, the Company issued a press release announcing the closing of the IPO and the exercise of the underwriters’ option to purchase 2,499,800 additional Units, a copy of which is attached as Exhibit 99.2 to this Current Report on Form 8-K.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

3

 

EXHIBIT INDEX

 

Exhibit No.   Description
1.1   Underwriting Agreement, dated December 14, 2021, by and between the Company and Citigroup Global Markets Inc., as representative of the underwriters.
     
3.1   Amended and Restated Memorandum and Articles of Association.
     
4.1   Warrant Agreement, dated December 14, 2021, by and between the Company and Continental Stock Transfer & Trust Company, as warrant agent.
     
10.1   Letter Agreement, dated December 14, 2021, by and among the Company, its executive officers, its directors, AACS LP and BDTCP Investments 2018, LLC.
     
10.2   Investment Management Trust Agreement, dated December 14, 2021, by and between the Company and Continental Stock Transfer & Trust Company, as trustee.
     
10.3   Registration Rights Agreement, dated December 14, 2021, by and among the Company, AACS LP and the Holders signatory thereto.
     
10.4   Private Placement Warrants Purchase Agreement, dated December 14, 2021, by and between the Company and AACS LP.
     
10.5   Administrative Services Agreement, dated December 14, 2021, by and between the Company and AACS LP.
     
99.1   Press Release, dated December 14, 2021.
     
99.2   Press Release, dated December 17, 2021.

 

4

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  AHREN ACQUISITION CORP.
     
  By: /s/ Elliot Richmond
    Name: Elliot Richmond
    Title:   Chief Financial Officer
     
Dated: December 17, 2021    

 

 

5